CLBT
Cellebrite DI Ltd.
Next earnings Aug 12, 2026 · consensus $0.11 EPS, $135M rev
$15.65
▲ +10.37%$15.65▼ -1.14%
over 1Y
L $11.03H $19.56
Today+10.4%
1W+23.9%
1M+4.5%
3M+11.8%
YTD-12.3%
1Y-1.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Revenue grew 18.6% YoY; but rich valuation (P/E 50.5).
Revenue (FY2025) $476M · FY2025
The read
Middling fundamentals and a rich price (~25% above fair value) leave little margin of safety — a wait-and-see.
Cellebrite DI Ltd. shows $476M in FY2025 revenue (+18.6% YoY), a 16.5% net margin, and 16.2% ROE.
Supporting the case: revenue grew 18.6% YoY; healthy net margin (16.5%); conservative balance sheet (liabilities/equity 0.94x).
Is CLBT a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~15.65
- Short call 16.5 @ ~1.41 est
debit $1,424max +$226max −$1,423BE 14.24
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $246M | $271M | $325M | $401M | $476M |
| Gross profit | $204M | $220M | $272M | $339M | $401M |
| Operating income | $13.8M | $1.04M | $33.2M | $56.9M | $66.5M |
| Net income | $71.4M | $121M | -$81.1M | -$283M | $78.3M |
| Diluted EPS | $0.44 | $0.59 | -$0.43 | -$1.35 | $0.31 |
| Net margin | 29.0% | 44.6% | -24.9% | -70.5% | 16.5% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$3.78B
EV / EBITDA48.2
EV / Sales7.9
EV / FCF23.6
P / FCF24.3
PEG (trailing)0.40
Earnings yield2.0%
FCF yield4.1%
Quality & risk
ROIC (est.)10.8%
Free cash flow$160M
Total debt—
Net cash$124M
Altman Z-Score6.03 safe
Piotroski F-Score4/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+4.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗144Filing2026-07-01open ↗144Filing2026-06-30open ↗144Filing2026-06-01open ↗4Period ending 2026-05-212026-05-26open ↗144Filing2026-05-21open ↗144Filing2026-05-21open ↗4Period ending 2026-05-182026-05-19open ↗144Filing2026-05-18open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗6-KPeriod ending 2026-05-142026-05-14open ↗
Frequently asked
- Is Cellebrite DI Ltd. (CLBT) a buy?
- CLBT currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 18.6% YoY; but rich valuation (P/E 50.5).
- What is CLBT's fair value?
- A Modified-Graham model based on CLBT's SEC fundamentals estimates a fair value of about $11.78. It is an estimate from reported earnings, not a price target.
- Is CLBT overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, CLBT currently appears overvalued relative to its SEC-grounded earnings power.
- What is Cellebrite DI Ltd.'s quality score?
- CLBT scores 70.17532748985715/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001854587, latest 144 filed 2026-07-01) · EODHD · as of 7/5/2026, 1:18:52 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 9:18 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.